tiprankstipranks
Trending News
More News >
OMRON Corporation (JP:6645)
:6645
Advertisement

OMRON (6645) AI Stock Analysis

Compare
5 Followers

Top Page

JP:6645

OMRON

(6645)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - 4o)
Rating:61Neutral
Price Target:
¥4,077.00
▲(5.51% Upside)
OMRON's strong financial performance, characterized by robust profitability and cash flow, is the primary driver of its stock score. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The dividend yield offers some compensation for investors.

OMRON (6645) vs. iShares MSCI Japan ETF (EWJ)

OMRON Business Overview & Revenue Model

Company DescriptionOMRON Corporation engages in industrial automation, electronic and mechanical components, social systems, and healthcare businesses worldwide. The company's Industrial Automation Business offers sensors, switches, safety and control components, relays, automation systems, motion/drives, robotics, energy conservation support/environment measure equipment, and power supplies. Its Electronic and Mechanical Components Business provides relays, switches, connectors, sensors, and components/units for amusement equipment. The company's Social Systems, Solutions and Service Business offers terminals and systems, including PV inverters and storage batteries; railway station systems, such as automated ticket gates and ticket vending machines, traffic and road management systems, payment systems, and UPS that protect equipment from unexpected power disruption; a range of solutions comprising software development and maintenance services to support the social infrastructure; and transport management systems and infrastructure monitoring systems. Its Healthcare Business offers blood pressure monitors; nebulizers; electrotherapy TENS devices; digital thermometers; body composition monitors; and other products, such as activity monitors, AEDs, etc. OMRON Corporation has an agreement with JMDC Inc. to jointly develop personalized aggravation and nursing care prevention solutions that support prescription medication treatments and patient lifestyle changes by predicting the risk of the onset of individual patient events. The company was formerly known as OMRON Tateisi Electronics Co. and changed its name to OMRON Corporation in January 1990. OMRON Corporation was founded in 1933 and is headquartered in Kyoto, Japan.
How the Company Makes MoneyOMRON generates revenue primarily through its diverse product offerings in industrial automation, healthcare, and other sectors. The company's revenue model is anchored in the sale of its products and solutions, which serve various industries, including manufacturing, healthcare, and infrastructure. Key revenue streams include the sale of industrial automation equipment, which accounts for a significant portion of its earnings, along with healthcare products that cater to both consumer and professional markets. Additionally, OMRON has established strategic partnerships and collaborations with other companies and organizations to enhance its technological capabilities and expand its market reach. These partnerships often lead to joint development projects and co-marketing initiatives that further drive sales and revenue growth. The company's focus on innovation and the development of IoT-enabled solutions also positions it well in the rapidly evolving technology landscape, contributing to its financial success.

OMRON Financial Statement Overview

Summary
OMRON exhibits a strong financial position with improving profitability and cash flow metrics. The company has managed to enhance its margins and cash generation despite fluctuations in revenue growth. The balance sheet remains solid, though attention to rising debt levels is necessary.
Income Statement
75
Positive
OMRON's income statement shows a strong gross profit margin of 44.18% TTM, indicating efficient cost management. The net profit margin improved significantly to 4.05% TTM from 2.03% in the previous year, reflecting enhanced profitability. However, revenue growth has been volatile, with a notable increase of 71.9% TTM after a decline in the previous periods. The EBIT and EBITDA margins are stable, suggesting consistent operational performance.
Balance Sheet
70
Positive
The balance sheet reveals a healthy debt-to-equity ratio of 0.27 TTM, indicating moderate leverage. Return on equity has improved to 4.21% TTM, showing better utilization of equity to generate profits. The equity ratio remains strong at 56.78%, reflecting a solid capital structure. However, the increase in total debt over the periods could pose a potential risk if not managed carefully.
Cash Flow
80
Positive
OMRON's cash flow statement highlights a robust free cash flow growth of 104.08% TTM, demonstrating strong cash generation capabilities. The operating cash flow to net income ratio of 0.28 TTM indicates efficient conversion of earnings into cash. The free cash flow to net income ratio of 0.22 TTM shows a healthy cash flow position, supporting future investments and debt servicing.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue807.52B801.75B818.76B876.08B762.93B655.53B
Gross Profit356.75B357.14B346.46B393.88B346.83B298.35B
EBITDA81.46B62.45B65.77B125.00B110.08B87.84B
Net Income32.71B16.27B8.11B73.86B61.40B43.31B
Balance Sheet
Total Assets1.37T1.36T1.35T998.16B930.63B820.38B
Cash, Cash Equivalents and Short-Term Investments156.91B149.02B143.09B105.28B155.48B250.75B
Total Debt210.35B157.12B172.76B45.37B60.12B38.89B
Total Liabilities429.37B427.36B403.74B266.93B262.66B211.02B
Stockholders Equity776.87B771.88B786.69B728.47B665.23B606.86B
Cash Flow
Free Cash Flow13.86B6.79B-503.00M8.44B34.07B67.17B
Operating Cash Flow63.35B55.78B44.88B53.46B67.43B93.83B
Investing Cash Flow-50.46B-47.89B-107.10B-55.53B-150.16B-14.79B
Financing Cash Flow-9.43B-4.61B85.99B-58.76B-29.60B-20.35B

OMRON Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3864.00
Price Trends
50DMA
4114.51
Negative
100DMA
3951.20
Negative
200DMA
4102.92
Negative
Market Momentum
MACD
4.94
Positive
RSI
34.95
Neutral
STOCH
16.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6645, the sentiment is Negative. The current price of 3864 is below the 20-day moving average (MA) of 4322.50, below the 50-day MA of 4114.51, and below the 200-day MA of 4102.92, indicating a bearish trend. The MACD of 4.94 indicates Positive momentum. The RSI at 34.95 is Neutral, neither overbought nor oversold. The STOCH value of 16.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6645.

OMRON Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$720.96B25.8213.68%1.09%21.48%65.56%
76
Outperform
$1.27T22.388.05%1.61%0.96%3.22%
75
Outperform
$1.23T23.5810.84%1.56%3.92%9.99%
74
Outperform
$553.22B37.954.19%2.37%3.97%-41.79%
72
Outperform
$698.52B23.178.09%2.37%11.18%-0.75%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
61
Neutral
$875.30B26.773.60%2.45%3.51%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:6645
OMRON
3,864.00
-1,454.07
-27.34%
JP:6965
Hamamatsu Photonics KK
1,604.50
-118.72
-6.89%
JP:6806
HIROSE ELECTRIC CO
18,155.00
-248.55
-1.35%
JP:6479
MinebeaMitsumi
2,916.00
375.70
14.79%
JP:7701
Shimadzu
4,223.00
-345.80
-7.57%
JP:4186
Tokyo Ohka Kogyo Co
5,881.00
2,271.36
62.93%

OMRON Corporate Events

OMRON Corporation Reports Strong Sales Growth Amid Challenges
Nov 8, 2025

OMRON Corporation, a leading player in the industrial automation and healthcare sectors, has released its financial results for the first half of the fiscal year ending March 31, 2026, showcasing its diverse business operations across various sectors.

OMRON Unveils Medium-Term Roadmap for Sustainable Growth
Nov 7, 2025

OMRON Corporation has announced the approval of its ‘Medium-Term Roadmap SF 2nd Stage,’ a strategic plan set to guide the company from FY2026 to FY2030. This roadmap follows the completion of the ‘NEXT 2025’ Structural Reform Program and aims to transition OMRON’s business portfolio towards sustainable, profit-driven growth, thereby increasing corporate value.

The most recent analyst rating on (JP:6645) stock is a Buy with a Yen4900.00 price target. To see the full list of analyst forecasts on OMRON stock, see the JP:6645 Stock Forecast page.

OMRON Corporation Reports FY2025 H1 Financial Results with Revised Forecasts
Nov 7, 2025

OMRON Corporation reported an increase in consolidated revenue for the first half of FY2025, although profits declined due to lower gross profit margins and growth investments. The Industrial Automation Business (IAB) saw revenue and profit growth, driven by recovery in the customer base and strong demand in key industries. The Healthcare Business (HCB) initially experienced a decline but rebounded in the second quarter. The company revised its full-year forecasts, expecting higher revenue and profit, and maintained its dividend guidance. Structural reforms continue to support sales growth, aligning with the company’s strategic plan.

The most recent analyst rating on (JP:6645) stock is a Buy with a Yen4900.00 price target. To see the full list of analyst forecasts on OMRON stock, see the JP:6645 Stock Forecast page.

OMRON Announces Interim Dividend and Year-End Forecast Revision
Nov 7, 2025

OMRON Corporation announced the approval of an interim dividend and a revision of the year-end dividend forecast for the fiscal year ending March 31, 2026. The interim and year-end dividends are set at 52.00 yen per share, maintaining the full-year dividend forecast at 104.00 yen. This decision aligns with OMRON’s cash allocation and shareholder return policies during its restructuring period, emphasizing investments in long-term value creation and stable shareholder returns.

The most recent analyst rating on (JP:6645) stock is a Buy with a Yen4900.00 price target. To see the full list of analyst forecasts on OMRON stock, see the JP:6645 Stock Forecast page.

OMRON Reports First Half Financial Results and Dividend Announcement
Nov 7, 2025

OMRON Corporation reported its consolidated financial results for the first half of the fiscal year ending March 31, 2026, showing a 5% increase in net sales compared to the same period last year. Despite the rise in sales, operating income decreased by 7.8%, reflecting challenges in operational efficiency. The company also announced an interim dividend of 52 yen per share, maintaining its annual dividend forecast, indicating a stable return for shareholders.

The most recent analyst rating on (JP:6645) stock is a Buy with a Yen4900.00 price target. To see the full list of analyst forecasts on OMRON stock, see the JP:6645 Stock Forecast page.

OMRON Plans Spin-Off of Device & Module Solutions Business
Sep 19, 2025

OMRON Corporation’s Board of Directors has initiated discussions to spin off its Device & Module Solutions Business (DMB) by April 1, 2026. This move aims to establish an independent management structure for DMB to enhance agility, cost-competitiveness, and investment in new product development, amidst growing market demand and competitive pressures.

The most recent analyst rating on (JP:6645) stock is a Buy with a Yen4232.00 price target. To see the full list of analyst forecasts on OMRON stock, see the JP:6645 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 11, 2025